Insurance Won't Cover Your GLP-1? Every Alternative Path

Your insurance denied coverage for your GLP-1 medication. You're not alone — millions of Americans face this every year. But a denial isn't the end of the road. There are multiple alternative pathways to access weight loss medication, from appeals to manufacturer programs to emerging government coverage. This guide covers every option.

Option 1: Appeal the Denial

Insurance denials can often be overturned. The first step is understanding why you were denied. Common reasons include formulary exclusion (the drug isn't on your plan's covered list), prior authorization failure (your documentation was incomplete), step therapy requirements (your plan requires you to try a cheaper option first), or a blanket weight-loss-drug exclusion in your employer's benefit design.

If the denial is based on incomplete documentation — not a blanket exclusion — an appeal with stronger supporting evidence has a reasonable chance of success. Ask your prescriber to write a letter of medical necessity that includes your BMI, documented comorbidities, history of failed lifestyle interventions, and clinical rationale for the specific medication. Include lab results and any relevant specialist notes.

Option 2: Manufacturer Savings Programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound, Foundayo) operate savings programs that can dramatically reduce out-of-pocket costs. Novo Nordisk's commercial savings card reduces copays to as low as $25/month for commercially insured patients whose plans cover Wegovy. For self-pay patients, Novo launched a subscription program in March 2026 with fixed monthly pricing through select telehealth partners. Eli Lilly's LillyDirect offers Zepbound at $299/month and Foundayo starting at $149/month for eligible patients.

Option 3: Medicare GLP-1 Bridge (Starting July 2026)

If you're on Medicare, the GLP-1 Bridge program provides coverage for Wegovy (all formulations), Foundayo, and Zepbound KwikPen at a $50 monthly copay. The program runs from July 1, 2026 through December 31, 2027. Your provider must submit a prior authorization, and you must be enrolled in a qualifying Part D plan.

Option 4: State Medicaid Programs

Thirteen states currently cover GLP-1 medications for weight loss through Medicaid, including Arizona, Colorado, Connecticut, Illinois, Louisiana, Massachusetts, New Mexico, New York, Oregon, Rhode Island, Vermont, Washington, and Arkansas. Three states — California, Pennsylvania, and Michigan — eliminated coverage in January 2026. Check your state's current Medicaid formulary.

Option 5: Telehealth Cash-Pay Programs

Multiple telehealth platforms offer fixed monthly pricing that bypasses insurance entirely. Brand-name GLP-1 options through telehealth typically cost $149–$349/month depending on the medication and dose. These programs often bundle the provider consultation, prescription, and medication delivery into a single monthly fee.

Option 6: Alternative FDA-Approved Medications

If GLP-1 medications are out of reach, older FDA-approved options are more affordable. Phentermine is available as a low-cost generic (often under $30/month) for short-term use. Qsymia and Contrave cost $100–$250/month and may be covered by plans that exclude GLP-1s. Orlistat (Alli) is available over the counter without a prescription.

Option 7: Employer Advocacy

If your employer's plan excludes weight loss medications, you can advocate for change. Benefits decisions are reviewed annually, and employee feedback influences them. Write to your HR department explaining the medical need, referencing the growing evidence base, and noting that treating obesity reduces downstream healthcare costs. Some employers have added GLP-1 coverage after employee advocacy.